TidalSense
Cambridge healthtech company that raised £14.2m in July 2026.
TidalSense, a Cambridge respiratory-diagnostics company, raised £14.2m on 24 July 2026 from a four-investor syndicate with no disclosed lead, for its handheld COPD-diagnosis sensor N-Tidal.
Last refreshed: 31 July 2026 · Appears in 1 active topic
TidalSense raised £14.2m from four investors with no named lead; who actually priced the round?
Timeline for TidalSense
Raised £14.2m from a four-investor syndicate
UK Startups and Innovation: TidalSense takes £14.2m with no leadBackground
TidalSense, formerly Cambridge Respiratory Innovations, was founded in 2013 to build faster, easier tools for diagnosing chronic respiratory disease. Its core product, N-Tidal, is a handheld sensor that identifies COPD from around 75 seconds of normal breathing, avoiding the forceful exhalation that conventional spirometry requires of patients.
The device received an EU CE mark in March 2025, clearing a key regulatory hurdle for use in European healthcare settings. As a diagnostics company, TidalSense's commercial PATH runs through health-service procurement and clinician adoption rather than consumer sales, a slower but potentially more durable route to revenue once cleared.
The company's rebrand from Cambridge Respiratory Innovations to TidalSense accompanied its shift from an academic-adjacent research name to a market-facing medical-device identity.
TidalSense raises money without a lead
TidalSense raised £14.2m on 24 July 2026 from four investors, Cross-Border Impact Ventures, BGF, Airstream Capital and Foresight Group, none named as lead. A lead investor normally sets a round's price, negotiates terms and takes a board seat; TidalSense's syndicate has none of that structure.
The gap fits a company, formerly Cambridge Respiratory Innovations, whose principal risk sits with regulators and health-service procurement rather than the open market. Its handheld sensor N-Tidal, which diagnoses COPD from around 75 seconds of normal breathing rather than forceful spirometry, received an EU CE mark in March 2025, meaning TidalSense's next hurdles are clinical adoption and reimbursement, not investor pricing.